Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGEN), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. This news page highlights company announcements, clinical updates and capital markets developments that relate to NervGen’s progress.
Readers can find coverage of NervGen’s listing and trading on Nasdaq under the symbol NGEN, along with commentary from the company on how this listing fits into its evolution as a biopharmaceutical issuer. News items also describe the company’s clinical milestones, including data from the Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291 in individuals with chronic spinal cord injury.
The company reports that NVG-291, a subcutaneously administered neuroreparative peptide, has demonstrated durable improvements in function, independence and quality of life in chronic SCI, supported by changes in corticospinal and reticulospinal signaling. Updates on regulatory interactions, such as FDA Type C and planned End-of-Phase 2 meetings, are also reflected in NervGen’s news flow, as the company works to define the development and registration pathway for NVG-291.
Because NervGen focuses on conditions with significant unmet medical need, its news often centers on clinical trial data, regulatory designations such as FDA Fast Track and EMA Orphan Drug status for NVG-291 in spinal cord injury, and strategic steps toward late-stage development. Investors and observers can use this page to follow how NervGen describes its progress in advancing NVG-291 and its next-generation candidate NVG-300 within the broader context of neurotrauma and neurologic disease research.
NervGen (NASDAQ:NGEN) will ring the Nasdaq closing bell on January 22, 2026 in New York City to mark its recent Nasdaq listing. Adam Rogers, MD, Chairman and Interim CEO, will be joined by management, board members, advisors and guests. The ceremony broadcast begins at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower and available on Nasdaq’s X and Facebook pages. The event highlights NervGen’s focus on developing neuroreparative therapeutics for spinal cord injury.
NervGen Pharma (NASDAQ:NGEN) announced its common shares began trading on Nasdaq on January 8, 2026. The company is a clinical-stage biopharmaceutical developer of neuroreparative therapeutics, advancing NVG-291 for spinal cord injury (SCI).
Recent expanded Phase 1b/2a CONNECT SCI data (announced Nov 24, 2025) showed statistically significant improvements in upper-limb corticospinal signaling and reductions in hyperactive reticulospinal signaling, with reported durable functional and quality-of-life gains in chronic SCI. NervGen plans an FDA End-of-Phase 2 meeting in early 2026 to align on development and registration pathways.